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Bacterial  endotoxin (lipopolysaccharide  [LPS]) causes fatal shock in humans and experimental 
animals. The shock is mediated by cytokines released by direct LPS stimulation of cells of monocyfic 
origin (monocyte/macrophage  [MO]). Recent studies have supported the concept that the plasma 
protein, LPS binding protein (LBP),  plays an important role in controlling MO responses to 
LPS. Specifically, evidence has been presented to suggest that CD14, a membrane protein present 
in MO, serves as a receptor for complexes of LPS and the plasma protein LPS binding protein 
(LBP). In this function CD14 mediates attachment of LPS-bearing particles opsonized with LBP 
and appears to play an important role in regulating cytokine production induced by complexes 
of LPS and LBP. The CD14-, murine pre-B cell line 70Z/3 responds to LPS by synthesis of 
tc light chains and consequent expression of surface IgM. To better understand the role of CD14 
in controlling cellular responses to LPS, we investigated the effect of transfection of CD14 into 
70Z/3 cells on LPS responsiveness. We report here that transfection of human or rabbit CD14 
cDNA into 70Z/3 cells results in membrane expression of a glycosyl-phosphatidylinositol-anchored 
CD14. When LPS is complexed with LBP, CD14-bearing 70Z/3 cells bind more LPS than do 
the parental or 70Z/3 cells transfected with vector only. Remarkably, the expression of CD14 
lowers the amount of LPS required to stimulate surface IgM expression by up to 10,000-fold 
when LPS dose-response curves in the CD14-, parental and CD14-bearing, transfected 70Z/3 
cells are compared. In contrast, the response of CD14-bearing 70Z/3 cells and the parental 70Z/3 
cell line (CD14-) to interferon 'y is indistinguishable.  LPS stimulation of the parental and CD14- 
bearing 70Z/3 cells results in activation of NF-kB. These data provide evidence to support the 
concept that the LPS receptor in cells that constitutively express CD14 may be a multiprotein 
complex containing CD14 and membrane protein(s) common to a diverse group of LPS-responsive 
cells. 
T 
he endotoxin, or LPS, of Gram-negative bacteria is one of 
the most potent bacterial toxins known. Picomolar con- 
centratiom of LPS induce pathophysiologic changes in humans 
and experimental animals (1--6) that include enhanced leuco- 
cyte adherence to endothelial ceils, fibrin deposition in a va- 
riety of organs, fever, hypotension, and alterations in cellular 
energy metabolism. These changes result in the often fatal 
syndrome known as septic shock or multi-organ faihire (7, 
8). In humans and experimental animals, it is well established 
that cytokines released from LPS-stimulated monocytes/mac- 
rophages (MO) 1 mediate many of the cellular changes that 
cause septic shock (1-5). 
1 Abbreuiations used in this paper: GPI, g|ycosyl-phosphatidylinositol;  LBP, 
LPS binding protein; MO, monocytes/macrophages;  PFPLC, phospha- 
tidylinositol-specitic  phospholipase  C; RSV, Rous Sarcoma Virus. 
There is ample, albeit circumstantial, experimental data to 
support the contention that LPS acts via a specific plasma 
membrane receptor (9-16).  Despite the remarkable progress 
during the past decade in identifying and characterizing the 
properties of membrane receptors for nearly every type of 
biologically active substance, there is little information about 
the molecular identity of LPS receptors in MO. Given the 
important role for LPS in human disease, it is important to 
bridge this gap in our knowledge. 
The biological activity of LPS is substantially modified by 
plasma proteins, and recent studies from our laboratory have 
identified a novel, receptor dependent pathway of MO stim- 
ulation that involves complexes of LPS and the plasma pro- 
tein LPS binding protein (LBP) (12, 17, 18). LPS-LBP com- 
plexes interact with MO via a membrane receptor identified 
as CD14 (18). CD14 is a 55-kD glycosyl-phosphatidylinositol 
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of all cells of monocytic  origin (19-21). In this function CD14 
serves as a receptor for LPS-bearing partides opsonized with 
LBP and appears to play an important role in regulating LPS- 
induced cytokine responses  (12, 18,  19). 
Because LPS also stimulates cells that do not express CD14, 
there seems to be both CD14-dependent and CD14-indepen- 
dent pathways for LPS-induced cell activation. In this regard 
several different membrane proteins distinct from CD14 have 
been suggested to serve as LPS receptors  in both MO and 
other LPS-responsive  cell types (9-16).  However, relation- 
ships between CD14-dependent and -independent pathways 
for LPS stimulation have not been elucidated. 
Herein we describe experiments with a murine pre-B cell 
line, 70Z/3, that is induced by LPS or cytokines such as IFN-3, 
to synthesize r  light chains,  and as a consequence expresses 
surface IgM (12). We have transfected this CD14-  cell line 
with human or rabbit CD14 and the resulting transfected 
cells constitutively express surface-bound CD14. The CD14 + 
70Z/3 cells bind LPS by LBP/CD14-dependent mechanisms; 
surface IgM expression  can be induced by 10,000-fold  less 
LPS than that required in parental or vector-transfected 70Z/3 
cells. In contrast, IgM induction by IFN-3~ is identical in pa- 
rental, control transfectants or CD14 + transfectants. These 
data provide support for the contention that the CD14 plays 
a crucial role in recognition of LPS and that the LPS receptor 
on MO may be multimeric containing CD14 and an as yet 
unidentified additional membrane protein(s). 
Materials  and Methods 
LPS.  Re595  LPS was isolated from lyophilized  Salmonella min- 
nesota Re595 bacteria as described (1). LPS from Escherichia coli 
0111:B4 was purchased from List Biological Laboratories (Camp- 
bell, CA) and synthetic lipid A was purchased from ICN Biomed- 
icals, Inc. (Costa Mesa, CA). Stock solutions of LPS or synthetic 
lipid A were prepared, stored, and utilized as described (22). LBF 
was isolated from acute phase rabbit serum as described (23). 
mAbs.  The anti-human CD14, MY4 (IgG2b), was purchased 
from Coulter Immunology (Hialeah, FL), and the anti-human 
CD14, 63D3, was isolated from culture supernatants of the hy- 
bridoma cell  line (HB44; American  Type Culture Collection, Rock- 
ville, MD); the rat anti-routine CD45 (B220) mAb 14.8 (24) was 
a gifr from P. Linton (The Scripps Research Institute, La  Jolla, CA); 
IgG2b mAbs against the c~ subunit of human chorionic gonado- 
tropin (Biodesign,  Pasadena,  CA) or human o~-l-antitrypsin  (Zymed 
Laboratories, San Francisco, CA) were used as controls for MY4; 
FITC-conjugated goat anti-murine IgG was purchased from Gibco 
Laboratories (Grand Island, NY). Sodium azide was removed  from 
mAb solutions by dialysis against sterile, pyrogen-free PBS, 
Cells.  Parental  or transfected 70Z/3 cells were cultured as de- 
scribed (13). 
Other Reagents.  F(ab')z  preparations of FITC-conjugated  rabbit 
anti-murine IgM or FITC-conjugated rabbit anti-rat IgG were ob- 
tained from Zymed  Laboratories. Pliosphatidylinositol-specific  phos- 
pholipase C (PI-PLC) was a gift from M. Low (Columbia Univer- 
sity, New York) and used as described (25). Recombinant routine 
IFN-3, was a gift of K. D. Schreiber (Washington University, St. 
Louis, MO). 
Rabbit and Human CD14 eDNA.  The details of  cloning rabbit 
CD14 from an EMBL3 rabbit genomic library (Clonteeh) and iso- 
lation of rabbit CD14 cDNA will be described elsewhere (Lee, 
J.-D., manuscript in preparation). The nudeotide sequence  of  rabbit 
CD14 eDNA has been entered in GenBank  (accession  no. M85233). 
Amino acid sequence comparisons from deduced amino acid se- 
quences revealed  that rabbit CD14 gene shows 73% and 64% iden- 
tity with human and routine CD14, respectively. A full-length 
eDNA clone of human CD14 was a generous gift from B. Seed, 
(Massachusetts Institute of Technology, Boston, MA) (21). 
Expression of Rabbit and Human CDI4 in 70Z/3 Cells.  The 
coding region of human or rabbit CD14 was cloned into the XbaI 
site of a eucaryotic expression vector, pRe/RSV (Invitrogen, San 
Diego, CA) containing a neomycin resistance gene for the selec- 
tion of stable transformants and a Kous Sarcoma  Virus (RSV) LTR 
promoter for transcription initiation of inserted DNA. Electropo- 
ration was used to transfer the pRc/RSV constructs containing 
rabbit or human CD14 or the pRe/RSV vector only into 70Z/3 
cells as described (26), except that a 400-V/cm, 20-ms pulse was 
used. G418 (1 mg/ml) was used for stable transformant selection 
as described (26). Identification of the presence of surface CD14 
in transfected 70Z/3  cells was performed with mAbs to CD14, 
MY4, or 63D3, by standard procedures using FITC goat anti-mu- 
fine IgG as a second antibody. 
PCR Analysis of 70Z/3 Cells.  Poly(A)  §  RNA was isolated 
from RAW 264.7 or 70Z/3 cells with a Micro Fast Track Kit (In- 
vitrogen) and first-strand eDNA was synthesized using oligo(dT) 
as a primer as described (27). PCR were performed as described 
(27) annealing at 56~  These reactions used 1 U/reaction of Per- 
fect Match DNA polymerase  enhancer (Stratagene, La  JoUa, CA). 
Synthetic oligonucleotides  specific  for routine CD14 were prepared 
from the published sequence (28): 5'-CGTCTAGAAGAACACCA- 
TCGCTGTAAAG-Y; 5  '-  GCTCTAGAAT'I~CGTTGAC  GAGGAC  - 
CCGC:Y; and for rabbit CD14 as recorded in GenBank (accession 
no.  M85233):  5'-CGTCTAGAACCATGGAGCCCG'/GCCCT- 
GCT-Y; 5  ~ C CTCTAGATTAGATAAGC  C C  CTGC  -  y. 
Stimulation of Surface IgM Expression in 70Z/3 Cells.  Parental 
or transfected 70Z/3 cells were cultured in T-75 flasks  with RPMI 
1640 containing 10 mM Hepes, 10% FCS, 2 mM t-glutamine, 0.05 
mM 2-ME, and antibiotics as described (13). Cells used to measure 
!gM expression  were removed  from T-75 cultures and washed three 
times with serum-free  RPMI 1640 containing Hepes, t-glutamine, 
2-ME, and antibiotics as described (13). The washed  cells  were then 
placed into 48:'well plates (Costar, Cambridge, MA) in 0.5 ml of 
RPMI 1640 at a cell density of 2 x  10  +  cells/ml under serum-free 
conditions; in some experiments, FCS was added as noted in the 
text or figure legends. In experiments performed under serum-free 
conditions, purified LBP was added to the cells immediately fol- 
lowed by the addition of LPS. Surface IgM expression in 70Z/3 
cells stimulated with LPS or other agonists was quantitated in flow 
cytometry studies with an F(ab')2, FITC rabbit anti-murine IgM 
(Zymed Laboratories) as described (13, 26); data are expressed as 
the percent of cells expressing surface IgM. The specificity  of the 
fluorescence changes detected was  confirmed using  a  control 
F(ab')z, FITC rabbit  anti-rat IgG (Zymed Laboratories). Flow 
cytometry analysis  was performed using a FACScan  |  instrument, 
and data were analyzed  with the LYSIS  U computer program (Becton 
Dickinson Immunocytometry Systems,  Mountain View, CA). Data 
for IgM expression are reported for an individual experiment; all 
experiments have been replicated at least twice yielding similar 
results. 
Measurement of  NF-kB Activation.  NF-kB  activity was measured 
in nuclear extracts exactly as previously described (29, 30). 
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Expression of CD14 in 70Z/3 Cells.  We made pRc/RSV 
constructs containing full-length cDNA for either rabbit or 
human CD14 (21) and transfected 70Z/3 cells with the com- 
plete construct (70Z/3-rCD14 or 70Z/3-hCD14) or the vector 
alone (70Z/3-RSV). Identification of  stable clones expressing 
CD14 was accomplished using flow cytometry  of  cells stained 
with the anti-human CD14 mAb MY4 (31) that also cross- 
reacts with native rabbit CD14 (R. J. Ulevitch, unpublished 
data).  Surface expression of CD14 in the transfectants was 
established by treatment of cells with PI-PLC, before anti- 
body staining. Flow cytometry  data from studies of  70Z/3 cells 
transfected with human CD14 cDNA (70Z/3-hCD14) ana- 
lyzed with MY4 before and after PI-PLC treatment are shown 
in Fig.  1. As a control we stained the 70Z/3-hCD14 with 
an anti-murine CD45 mAb since this membrane protein is 
expressed on the surface of 70Z/3 cells, but is not GPI linked 
(32). Staining of 70Z/3-hCD14 cells with MY4 revealed a 
homogeneous population of fluorescent cells not detected 
when MY4 was replaced by an isotype control mAb. Iden- 
tical staining was observed with another anti-human CD14 
antibody, 63D3 (data not shown). Importantly, staining with 
MY4 was lost in cells treated with PI-PLC. In contrast, PI- 
PLC pretreatment did not change the reactivity with the anti- 
CD45 mAb. An identical set of observations were recorded 
in studies  with 70Z/3 cells transfected with rabbit  CD14 
cDNA (70Z/3-rCD14)  (data not shown). There are no mAbs 
to murine CD14 presently available that would permit es- 
tablishing  the absence of CD14  expression on parental or 
70Z/3-RSV  cells by means  of flow cytometry or surface 
labding/immunoprecipitation studies. Since the cDNA se- 
quence of murine CD14 is known (20, 28), we were able 
to use PCR to verify the absence of routine CD14 mRNA 
in 70Z/3 cells. Primers specific for murine and rabbit CD14 
were synthesized and used to quantify expression of murine 
or rabbit CD14 mRNA in 70Z/3-RSV or 70Z/3-rCD14 cells. 
The murine macrophage-like cell line RAW 264.7 was used 
as a source of  murine CD14 mRNA to confirm the specificity 
of the primers and PCR reaction. The results of this experi- 
ment shown in Fig. 2 demonstrate that a strong mRNA (1.3- 
kb) band was detected in RAW264.7 cells with the murine 
CD14-specific primers. PCR analysis  of  RAW264.7 cels with 
rabbit  CD14-specific  primers  also revealed a much weaker 
signal at 1.3 kb. This is not surprising considering the highly 
conserved sequences ofmurine and rabbit CD14. In contrast, 
no PCR product was observed in either 70Z/3-RSV or 70Z/3- 
rCD14 cells  using murine CD14-specific  primers. Importantly, 
however, the rabbit CD14-specific primers revealed a strong 
signal of appropriate size (1.3 kb) in the 70Z/3-rCD14 cells. 
In control experiments we ascertained that if the 70Z/3 cells 
contained 1/1,000 of the routine CD14 mRNA present in 
RAW264.7 cells our PCR strategy would detect this. 
The 1.3-kb PCR product detected in RAW 264.7 cells 
and in 70Z/3-rCD14  calls was isolated,  subdoned into a 
pRc/CMV vector, and sequenced.  We obtained sequences  iden- 
tical to the known nucleotide sequences of murine (20, 28) 
or rabbit CD14 cDNA, respectively (GenBank accession no. 
M85233). 
LBP/CD14-dependent  Binding  of  FITC-LPS to 70Z/3-hCDI4 
Cells.  We next performed experiments to compare binding 
of LPS to 70Z/3-RSV or 70Z/3-hCD14 cells. To do this we 
prepared a fluorescent derivative of Re595 LPS (FITC-LPS) 
and used flow cytometry  to examine binding at 22~  of  FITC- 
Re595 LPS to 70Z/3-RSV or 70Z/3-hCD14 cells. Binding 
of FITC-LPS was evaluated  in the presence or absence of  LBP. 
Control 
r  >= 
Control 
Fluorescence tntensity 
Figure  1.  FACS  |  analysis of 
70Z/3-hCD14 cells, 70Z/3 cells 
were stained with the mAb MY4 
(anti-human  CD14)  or  14.8 
(anti-murine CD45)  before  or 
after treatment with PI-PLC. PI- 
PLC treatment was performed as 
noted in the legend to ~ble 1. An 
IgG2b mAb  (anti-human o~-l- 
antitrypsin) and normal rat serum 
served as specificity controls. 
Figure 2.  PCR analysis  of  RAW 264.7 cells and 70Z/3-RSV or 70Z/3- 
rCD14  cells for CD14 mRNA, Procedures and composition of murine 
and rabbit specific primers are noted in Materials and Methods. M, PCR 
performed with murine CD14-specific primers; and R, PCR performed 
with rabbit-specific primers. 
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PI-PLC. These data are expressed as median channel number, 
a measurement that reflects the amount of FITC-LPS bound 
per cell. Results  of a single, representative experiment are 
shown in Table 1. In the absence of LBP, the median channel 
number was nearly identical in 70Z/3-RSV and 70Z/3-hCD14 
cells, and PI-PLC pretreatment did not reduce the median 
channel number. In contrast, an increase in median channel 
number in the presence of LBP was observed with 70Z/3- 
hCD14  cells. This  increase was  completely inhibited by 
pretreatment with PI-PLC. Under the conditions of this ex- 
periment PI-PLC treatment removes >90% of the CD14 ex- 
pressed in the 70Z/3-hCD14 cells as measured by staining 
with MY4. 
Two additional experiments to be described elsewhere (K. 
Kato, manuscript in preparation) provide evidence for the im- 
portance of CD14 expression in the binding of LPS to CD14- 
bearing 70Z/3 cells. Inclusion of the anti-human CD14 mAb 
MY4 or a 100-fold excess of nonfluoresceinated Re595 LPS 
reduced the median channel number to the values observed 
with 70Z/3-RSV cells or PI-PLC-pretreated 70Z/3-hCD14 
cells (data not shown). 
Functional Consequences of CDI4 Expression in 70Z/3 Cells. 
70Z/3 cells respond to LPS or cytokines such as IFN-3' by 
synthesizing  g light chains with subsequent expression of 
surface IgM (12, 13, 26, 33). To determine if CD14 expres- 
sion changes the response of 70Z/3 cells to these agonists, 
we quantitated surface IgM expression 24 h after stimulation 
with varying doses (1 pg/ml to 1/~g/ml) of LPS or IFN-7. 
To study LPS responses we used LPS isolated from rough 
(Re595 LPS) or smooth (0111:B4 LPS) form bacteria or syn- 
Table  1.  PI-PLC Pretreatment Inhibits LBP-dependent Binding 
of FITC-LPS to 70Z/3-hCD14  Cells 
Cell  LPS  LBP  PI-PLC  Median channel number 
70Z/3-1LSV 
70Z/3-hCD14 
-  -  -  2.16 
+  -  -  4.66 
+  -  +  4.63 
+  +  -  5.56 
+  +  +  5.29 
-  -  -  2.20 
+  -  -  4.31 
+  -  +  4.25 
+  +  -  8.27 
+  +  +  5.35 
thetic lipid A and compared cellular responses in the pres- 
ence or absence of added LBP. 
70Z/3 cells transfected with vector alone (70Z/3-1LSV) or 
70Z/3-rCD14 cells were placed in 48-weU plates in serum- 
free RPMI 1640 and stimulated with the two different LPS 
preparations or synthetic lipid A in the presence and absence 
of added LBP. Results from this experiment are shown in 
Fig. 3. Dose-response curves observed for the two different 
LPS preparations or synthetic lipid A using CD14-,  70Z/ 
3-RSV  cells were essentially the same in the presence and 
absence of added LBP. Moreover,  identical dose-response  curves 
were obtained using the parental 70Z/3 cells (data not shown). 
These studies also revealed that concentrations of LPS or syn- 
thetic lipid A >0.1/~g/ml are required to produce measur- 
able changes in surface IgM expression during the 24-h stim- 
ulation period.  In contrast to the LPS dose-response data 
obtained  with CD14-,  70Z/3 cells, stimulation of 70Z/ 
3-rCD14 with as little as 10 pg LPS/ml in the presence of 
LBP resulted in induction of surface IgM. In the presence 
of LBP, R_e595 or 0111:B4 LPS produced maximum responses 
with 0.1-1 ng LPS/ml, and synthetic lipid A was maximally 
active between 1 and 10 ng/ml. Thus, expression of CD14 
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PI-PLC treatment (2.5 U/ml) of 70Z/3-RSV or 70Z/3-hCD14  cells (106 
cells/ml) in HBSS was performed at 37~  for 60 min. After centrifuga- 
tion, the cells were resuspended  in I-IBSS  containing 0.1% BSA and 0.05% 
sodium azide; FITC-Re595 LPS (20 ng/ml) +  300 ng/ml rabbit LPB 
were  added the cells maintained for 30 min at 22~  and subjected to 
FACS  |  analysis. 
Figure 3.  Stimulation of 70Z/3-KSV cells (CD14-) or 70Z/3-rCD14 
cells (CD14 +) with varying doses of LPS (Re595 or 0111:B4 LPS) or syn- 
thetic lipid A. Stimulation in the presence of 100 ng/ml rabbit LBP (O 
and M) and in the absence of LBP (O and D). Surface IgM expression 
measured 24 h after addition of LPS or LPS-LBP is described in Materials 
and Methods. 
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of LPS required to stimulate surface IgM expression. Even 
in the absence of  LBP, the 70Z/3-rCD14 cells displayed sub- 
stantially increased sensitivity to LPS, suggesting that LPS 
can directly interact with CD14.  In the studies not shown 
here we observed the same effects using 70Z/3-hCD14 cells 
stimulated with Re595 LPS or Re595 LPS-LBP complexes. 
In studies with 70Z/3-hCD14 or 70Z/3-rCD14 we ob- 
served that we could replace LBP with 10% FCS, but not 
with albumin-containing medium (AIMoV medium; Gibco 
Laboratories) (data not shown). Subsequent experiments were 
therefore performed with either complexes of LPS and LBP 
in serum-free medium (RPMI 1640) or with medium con- 
taining FCS as noted in figure legends. 
To exclude the possibility  that transfection  itself and/or 
subsequent expression of CD14 nonspecifically changes the 
response of 70Z/3 cells to agonists unrelated to LPS, we evalu- 
ated the response of the parental or transfected 70Z/3 cells 
to IFN-% Unlike the marked effects of CD14 expression on 
LPS responses, data shown in Fig. 4 demonstrate that induc- 
tion of surface IgM by IFN-'I, in 70Z/3,  70Z/3-RSV,  or 
70Z/3-rCD14 cells  is identical. Comparable results were noted 
when IFN-y was used to stimulate 70Z/3-hCD14 cells (data 
not shown). 
LPS-induced NF-kB Activation in 70Z/3 Cells.  In 70Z/3 
cells induction of K  light chain synthesis by LPS or cytokines 
involves a marked increase in transcription  of x light chain 
mRNA. LPS stimulation has been shown to activate two 
nuclear factors, NF-kB and OTF-2 (12). In contrast,  IFN-3, 
induces surface IgM expression without activation of NF-kB 
(34,  35). Since both  NF-kB-dependent and -independent 
pathways for K light chain mRNA induction are available 
in 70Z/3 cells, we next asked whether the very low stimula- 
tory doses of LPS that stimulate CD14-bearing  70Z/3 cells 
also activate NF-kB. To do this we prepared nuclear extracts 
from 70Z/3-RSV or 70Z/3-rCD14 cells stimulated with LPS 
for 4 h and examined these extracts for NF-kB  activity in 
A 
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Figure 4.  Stimulation of 70Z/3 (parental cells, CD14-), 70Z/3-RSV 
(CD14-), or 70Z/3-rCD14 (CD14 +) cells  by recombinant murine IFN-3,. 
Cell culture performed in RPMI 1640 containing 10% FCS FACS  |  anal- 
ysis of  surface  IgM expression  performed  after  48 h are described  in Materials 
and Methods. 
Figure 5.  LPS-induced  NF-kB activation  in 70Z/3-RSV or 70Z/3-rCD14 
cells. Cells were maintained at 37~  for 4 h with Re595 LPS in RPMI 
1640 containing  5% FCS and nuclear extracts prepared as described (30). 
Nuclear extracts (2 Izg) were mixed with 0.1/~g of the 32P-NF-kB probe, 
and as noted in the figure, in alternating  lanes a 10-fold excess (+) of unla- 
baled NF-kB oligonudeotide was added. This mixture was subjected to 
dectrophoresis  in a 6% acrylamide gel, and after gel drying overnight, 
autoradiography  was performed. The details  of  methods are as described  (29). 
gel shift assays. Results shown in Fig. 5 indicate that stimu- 
lation of 70Z/3-rCD14 cells with  100 pg/ml Re595  LPS 
resulted in marked increase in NF-kB, indicating that the low 
concentrations of LPS that stimulate surface IgM expression 
also activate NF-kB. In contrast, while 100 ng/ml Re595 LPS 
stimulated  70Z/3-RSV to activate NF-kB,  an LPS dose of 
100 pg/ml was without effect. Northern blot analysis of 
light chain mKNA performed  with total RNA isolated from 
LPS-stimulated 70Z/3-KSV or 70Z/3-rCD14 cells revealed 
that in the absence of added LPS, K  light chain mKNA was 
not detectable in either cell type. Addition of as little as 100 
pg Re595/ml to 70Z/3-rCD14 cells  produced a strong g light 
chain mKNA signal at  12 h in the Northern blots,  while 
in contrast,  10 ng/ml Re595 LPS was required to achieve a 
comparable signal in 70Z/3-KSV cells (data not shown). 
Inhibition of LPS Stimulation of 70Z/3  Cells.  We next 
sought to show that CD14 plays a crucial role in mediating 
enhanced  responsiveness  to LPS by using a mAb against human 
CD14, MY4, to block LPS stimulation of  CD14-bearing cells. 
The result of pretreatment of 70Z/3-RSV or 70Z/3-hCD14 
cells with MY4 or an isotype control mAb on LPS or LPS- 
LBP stimulation is shown in Table 2. MY4 blocked effects 
of  both LPS and LPS-LBP complexes on 70Z/3-hCD14 calls. 
Raising theLPS concentration overcomes the inhibition, but 
required lO-100-fold more LPS to achieve comparable levels 
of IgM expression observed in 70Z/3 cells treated with an 
isotype control. In contrast,  MY4 has no effect on the LPS 
dose-response curve observed with 70Z/3-RSV cells. In ex- 
periments not shown here we have observed similar inhibi- 
tion with several  other murine mAbs (28C5 and 18E12) pro- 
duced by immunization with recombinant human CD14 
(R. J. Ulevitch, unpublished data). The IFN-3, dose-response 
1701  Lee et al. Table  2.  Effect of Anti-CD14  (MY4) on LPS-induced Stimulation of 70Z/3-RSV or 70Z/3-hCD14 Cells 
70Z/3-RSV ( - LBP)  70Z/3-hCD14 (- LBP)  70Z/3-hCD14 (+ LBP) 
LPS  -*  Isotype control*  MY4S  -  Isotype control  MY4  -  Isotype control  MY4 
ng/ml  ~  ~ 
0.001  _ll  .....  5  5  1 
0.01  ......  24  27  2 
0.1  -  -  -  9  9  1  45  51  12 
1  1.5  -  -  30  29  5  64  66  36 
10  15  7  16  51  50  24  66  66  49 
100  36  34  37  61  59  50  64  70  60 
1000  58  55  54  71  68  60  74  72  62 
* No pretreatment. 
* IgG2b mAb, anti-human alpha-l-anti trypsin; 10 #g/ml. 
S [MY4], 10/zg/ml. 
II No induction. 
for stimulation  of 70Z/3-RSV  or 70Z/3-hCD14  cells was 
not changed by the presence of MY4 (data not  shown). 
Discussion 
We have performed experiments with 70Z/3 cells, a mu- 
rine pre-B cell line that  responds to LPS by synthesis of r 
light chains and consequent surface expression of IgM (12, 
26). 70Z/3 cells do not express CD14, and LPS dose-response 
curves are identical in the presence and absence of LPS binding 
protein. Transfection of 70Z/3 cells with cDNA coding for 
human or rabbit CD14 resulted in a stable line expressing 
a GPI-linked CD14. LPS dose-response curves show that the 
presence of CD14 reduces the amount  of LPS required  to 
induce surface IgM up to 10,000-fold without changing the 
dose dependency of a cytokine agonist,  IFN-%  These data 
unequivocally show the importance of CD14 as a receptor 
for LPS and/or LPS-LBP complexes. Moreover, results in this 
report provide support for the contention that cells such as 
MO that  constitutively express CD14 recognize LPS by a 
receptor that includes CD14 and an as yet unidentified mem- 
brane protein(s) that may be similar in all LPS-responsive cells. 
Although several reports have suggested that human B cells 
and B cell lines express a CD14-1ike protein,  proof of the 
presence of authentic CD14 mRNA and/or protein is lacking 
(36-38). Here we show in several different ways that 70Z/3 
cells do not express CD14.  The parental  (data not shown) 
or 70Z/3-RSV cells displayed identical dose-response curves 
using LPS or LPS-LBP complexes with two different types 
of LPS as well as with synthetic lipid A. In contrast, all studies 
from our own and other laboratories using LPS-responsive 
cells that constitutively express CD14 consistently demon- 
strate marked enhancement  of LPS responses by LBP (17, 
18, 39). Moreover, in studies to be described elsewhere we 
show that the human monocyte-like cell line THP-1 fails to 
demonstrate LBP-dependent LPS responses until CD14 ex- 
pression  is  induced  after  treatment  with  1,25-dihydroxy 
vitamin D3 (R. J. Ulevitch, unpublished data).  Finally,  re- 
cent studies with human MO genetically deficient in CD14 
demonstrate reduced LPS binding  (40). 
More direct evidence for the absence of CD14 in the pa- 
rental 70Z/3 cells was obtained by PCR analyses with primers 
specific for murine CD14 in mKNA.  PCR failed to reveal 
the presence of murine CD14 mRNA transcripts in the pa- 
rental 70Z/3 (data not shown) or 70Z/3-RSV cells.  How- 
ever,  the  same  primers  detected  authentic  murine  CD14 
mKNA in the murine macrophage-like cell line RAW 264.7. 
The sensitivity of the PCR method allows for the detection 
of levels of CD14 mRNA that  are 1,000-fold less than  ex- 
pressed in the RAW 264.7 cells. PCR analysis with primers" 
specific for rabbit CD14 dearly demonstrated rabbit CD14 
mRNA in 70Z/3-rCD14  transfectants,  but not in 70Z/3- 
RSV cells. 
Evidence derived from several different experimental  ap- 
proaches shows that transfection of 70Z/3 cells with either 
rabbit or human CD14 cDNA results in surface expression 
of GPI-linked CD14. Using flow cytometry we demonstrated 
PI-PLC-sensitive  fluorescent labeling of CD14 transfected cells 
by mAbs known to detect CD14 (MY-4 and 63D3) (31). In 
studies not shown here, detergent-solubilized proteins from 
surface-radioiodinated 70Z/3-hCD14 cells analyzed by SDS- 
PAGE after immunoprecipitation with the anti-human CD14 
mAbs MY4 and 63D3 revealed protein bands identical to na- 
tive and recombinant human CD14 (R. J. Ulevitch, unpub- 
lished data). Thus, the totality of evidence is consistent with 
the conclusion that  70Z/3 cells do not express CD14, but 
that  CD14 expression can be achieved by transfection. 
Inclusion  of as little as  10 ng/ml  LBP was su~cient  to 
provide a maximum enhancement of the response of CD14 + 
transfectants to LPS; increasing the concentration of LBP up 
to 300/zg/ml provided no additional enhancement  and did 
1702  Lipopolysaccharide  and Membrane Receptor not inhibit (data not shown). Our recent studies of LBP en- 
hancement of LPS-induced cytokine production (40a) indi- 
cate that other LPS binding proteins, including bactericidal- 
permeability increasing protein (BPI),  which shares amino 
acid sequence identity with LBP, cannot substitute for LBP. 
Despite the identification of other LPS binding proteins in 
serum (41-45),  to date, LBP is unique in its effects of LPS 
responses. Although we have reported here that FCS can sub- 
stitute for purified LBP, the identity of the protein(s) in FCS 
responsible for this is not known and requires further study. 
Despite the remarkable effect of CD14 expression on LPS 
dose-response curves, the mechanism of action of LPS in the 
transfected 70Z/3 calls appears unchanged. Previous studies 
have demonstrated that stimulation of 70Z/3 cells by LPS 
is lipid A dependent (33),  as are the effects described here 
with CD14-bearing 70Z/3 cells. LPS stimulation of 70Z/3 
cells by LPS has been shown to involve new transcription 
of g light chain mRNA and depends on activation of several 
DNA binding proteins, including NF-tcB (12). Here we show 
that addition of 100 pg/ml LPS to 70Z/3-rCD14 cells acti- 
vates NF-kB while 70Z/3-RSV requires substantially more 
LPS to achieve comparable levels of NF-kB activation. Simi- 
larly,  Northern blot analysis has revealed marked increases 
in steady-state levels of K  light chain mRNA occurring with 
100 pg/ml LPS in CD14-bearing transfectants,  while the pa- 
rental or 70Z3-RSV cells required 100-1,000-fold  more LPS 
to observe comparable changes in mRNA (data not shown). 
The data reported herein raise the possibility that the LPS 
receptor on CD14-bearing ceUs such as MO may consist of 
several proteins, including CD14, and other as yet unidentified 
membrane protein(s) that are common in all LPS-responsive 
call types. We suggest that both CD14 as well as additional 
receptor component(s) bind LPS (lipid A), and binding to 
both proteins is required to achieve the marked sensitivity 
to LPS observed with the CD14 +,  70Z/3  cells. Previous 
studies from our laboratory suggested that CD14 is a receptor 
for complexes of LPS and LBP (18, 39). Observations reported 
here suggest this view may require modification since LPS 
dose-response studies and blocking studies with anti-CD14 
mAb suggest that CD14 may recognize LPS directly.  Bin- 
chemical studies underway in our laboratory may also help 
to clarify  this issue. 
The LPS receptor on MO may be similar to the high aflfinity 
receptor for Ib2, a heterodimer where the presence of both 
subunits is necessary for expression of the high affinity, func- 
tional IL-2 receptor complex, but independent expression of 
either the c~ or/3 subunits of the IL-2 receptor is sufficient 
to support low affinity IL-2 binding (46, 47). Parallels exist 
for LPS, since cells devoid of CD14 appear to bind LPS by 
receptor-dependent mechanisms and cells that do not bind 
LPS can be engineered to express CD14 and subsequently 
bind LPS (R. J. Ulevitch, unpublished data).  Furthermore, 
MO genetically deficient in CD14 display a marked reduc- 
tion in serum-dependent LPS binding (39). Alternatively, the 
LPS receptor may resemble the Ib6 receptor, which is a het- 
erodimer consisting of a ligand binding subunit and a non- 
ligand binding membrane glycoprotein (48). Whether binding 
to CD14 is sufficient to generate a transmembrane signal that 
causes cell stimulation is not yet known. Preliminary data 
suggest that complexes of LBP formed with LPS antagonists 
or partial lipid A structures that bind to CD14 do not stimu- 
late either 70Z/3-CD14 cells (g. J. Ulevitch, unpublished 
data). However, complete understanding of the role of CD14 
in transmembrane signaling requires extensive  study. 
Derivatives  of LPS containing photochemically activated 
crosslinkers (41) that incorporate a radioactive labd have been 
used to identify membrane proteins that function as LPS 
receptors (13-15).  Membrane proteins distinct from CD14 
have been radiolabeled  by crosslinking, but in no case has 
a single protein been isolated, characterized, and shown defini- 
tively to be involved in transmembrane signaling. Moreover, 
the published crosslinking studies have used LPS concentra- 
tions that are several  orders of magnitude higher than required 
for cell stimulation, thereby leading to questions about the 
specificity of crosslinking. The present studies point to new 
opportunities for crosslinking strategies to identify membrane 
proteins, in addition to CD14, that are involved in LPS-induced 
cell stimulation, under conditions where nonspecific interac- 
tions of LPS will be minimal. As these studies progress we 
should be able to better define the function of CD14 in relaying 
signals from LPS in the extracellular environment to the nu- 
cleus and the relationship of CD14 to other membrane pro- 
teins involved in LPS recognition. 
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